X

Drug Profile

Research programme: gene therapies - Janssen Biotech/Symvivo

Alternative Names: Gene therapies - Janssen Biotech/Symvivo

Latest Information Update: 01 Jul 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Janssen Biotech
Class Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Unspecified

Most Recent Events

01 Jul 2021 Preclinical trials in Unspecified in USA (Parenteral) (Symvivo Corporation pipeline, July 2021)
25 Nov 2020 Janssen Biotech in-licenses bacTRL™ gene delivery platform technology from Symvivo
25 Nov 2020 Early research in Unspecified in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com